Introduction
The incidence of small cell lung cancer (SCLC) has been declining in Japan, but still accounts for 10%-15% of lung cancer cases. 1 The majority of Japanese patients with lung cancer are diagnosed when the disease has already become regionally advanced or metastatic. SCLC is characterized by aggressive progression, early metastases and poor prognosis, despite being highly sensitive to chemotherapy.
Complex diagnostic and prognostic tools are cumbersome to use in clinical practice; clinicians require tools that are simple and straightforward. Recently, various 
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Minami et al laboratory biomarkers have been developed based on systemic inflammation or nutritional status. These biomarkers have been demonstrated to predict prognosis in various cancers.
The modified Glasgow prognostic score (mGPS) [2] [3] [4] is based on a combination of serum albumin level and C-reactive protein (CRP). The prognostic nutritional index (PNI) 5 is based on a combination of serum albumin level and absolute lymphocyte count. These two tools have been shown to predict prognosis for many solid tumors. In contrast to a large number of studies for non-SCLC, there have been only a few studies that report validated mGPS 6 and PNI 7, 8 for SCLC. These studies included patients at various stages of disease, undergoing various treatment protocols.
This study aimed to evaluate these two prognostic biomarkers for patients with advanced SCLC who had received platinum-based combination chemotherapy.
Patients and methods

Patient selection and study design
We retrospectively selected patients who met all the following criteria: 1) histologically or cytologically diagnosed SCLC; 2) clinical stage IIIB or IV in the seventh TNM classification of lung cancer by the Union for International Cancer Control, 9 because our practice did not adopt the staging system of the Veterans Administration Lung Study Group; 10 3) initiation of platinum-based combination regimen as the first-line chemotherapy between November 2007 and June 2016 at our institution, and 4) available pretreatment blood test and sufficient laboratory data. The exclusion criteria were as follows: 1) patients who had received non-platinum chemotherapy as the first-line therapy; 2) patients who had received concurrent or sequential curative-intent thoracic radiotherapy, though we accepted patients with concurrent palliative radiotherapy, and 3) patients who had initiated chemotherapy at other institutions and thereafter transferred to our hospital.
Baseline characteristics included sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), 11 smoking status, height, body weight and therapeutic data. Current smokers were arbitrarily defined as patients who had smoked within a year prior to the diagnosis. Pretreatment laboratory data obtained within 2 weeks prior to chemotherapy included: complete blood count, hemoglobin, red cell distribution width, creatinine clearance estimated by Cockcroft-Gault formula with addition of 0.2 mg/dL to serum creatinine concentration, 12 serum albumin, sodium concentration, lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and CRP. PNI was calculated according to the following formula as previously described: 5 10×serum albumin value (g/ dL)+0.005×peripheral lymphocyte count (/μL). Elevated CRP and hypoalbuminemia were combined to generate the mGPS. If CRP was >1.0 mg/dL and albumin <3.5 g/dL, we assigned a score of 2; CRP >1.0 mg/dL only was assigned a score of 1 and absence of these two abnormalities was assigned a score of 0.
13 Progression-free survival (PFS) and overall survival (OS) were calculated from the first day of chemotherapy to the date of documented progressive disease or death. Response to chemotherapy was based on Response Evaluation Criteria in Solid Tumors version 1.1.
14 The data cut-off date was March 31, 2017.
The Osaka Police Hospital ethics committee approved our study (number 685). Informed consent was waived because the study was retrospective with de-identified data.
Data analysis
We expressed continuous variables as mean ± standard deviation (SD) and discrete and categorical variables as frequency. We used Fisher's exact test for comparison of relative frequencies and Welch's t-test for comparison of continuous variables. Using the receiver operating characteristic curve and the outcome variable of response to chemotherapy, we selected the optimal cut-off values of PNI that provided the closest point to the left upper hand corner of the graph, and then divided our patients into two groups. We compared the survival times by the Kaplan-Meier method and the log-rank test. We used the Cox proportional hazard model in order to investigate the association between biomarkers and PFS or OS. We included all variables with a P value <0.1 in univariate analysis in the subsequent multivariate analyses. The results were described as hazard ratios (HR) and 95% confidence interval (CI). A P value <0.05 was defined as statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).
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Results
During the study period, 104 patients with stage IIIB or IV SCLC received chemotherapy. Among them, seven patients were excluded from the analysis due to lack of pretreatment albumin value. Thus, 97 patients met the inclusion and exclusion criteria. As of the data cut-off date, 6 patients were still alive, 13 were lost to follow-up, 78 were confirmed dead and 
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mGPS and PNI as prognostic indicators in SCLC 88 had experienced progressive disease during or after firstline chemotherapy. Concurrent with first-line chemotherapy, five patients received palliative radiotherapy. Three patients were palliated by thoracic radiotherapy for superior vena cava syndromes or tracheal stenosis, and two were treated for sciatica by lumbar irradiation.
In order to divide our patients into two groups, receiver operating characteristic curve analysis defined 44.3 (sensitivity 0.59, specificity 0.59, area under the curve 0.60, 95% CI 0.47-0.72) as the optimal cut-off value for PNI. Patients with mGPS 0-1 had better ECOG-PS (P=0.02) and higher body mass index (23.5±3.7 vs 21.3±4.2, P=0.02) than those with mGPS 2. Patients with high PNI (≥44. 3) had better ECOG-PS (P<0.01) and higher body mass index (24.1±3.6 vs 21.2±3.8, P<0.01). They were likely to receive cisplatin-based first-line regimen (P=0.02) and secondline chemotherapy (P=0.01). Compared with patients with mGPS 2, those with mGPS 0-1 had higher serum albumin levels and lower CRP values. Patients with high PNI (≥44.3) had higher absolute lymphocyte counts, higher serum albumin levels and lower CRP levels than those with low PNI (<44.3) ( Table 1) .
The OS of patients with mGPS 0-1 and high PNI (≥44.3) was significantly longer than that of those with mGPS 2 and low PNI (<44.3) (Figure 1 ). There was no significant difference in PFS according to mGPS and PNI ( Figure 2 ). ) (HR 0.50, 95% CI 0.31-0.75, P<0.01) to be favorable prognostic factors for longer OS, in addition to absence of brain metastasis and ECOG-PS (Table 3) . Neither mGPS nor PNI was a prognostic factor for PFS (Table 4) .
Discussion
This study demonstrated that mGPS and PNI are useful as prognostic factors for OS in advanced SCLC treated with the standard first-line regimen of platinum-based chemotherapy. We demonstrated that these simple and user-friendly prognostic tools are useful for patients with advanced SCLC treated with chemotherapy alone. Both mGPS and PNI were expected to be independent prognostic factors for OS in patients with SCLC treated with chemotherapy alone. We evaluated this by two means: first, multivariate Cox proportional hazard analysis detected both biomarkers as independent prognostic factors; second, Kaplan-Meier curves and log-rank tests showed that OS in patients with mGPS 2 and low PNI (<44.3) was significantly lower than that of patients with mGPS 0-1 and high PNI (≥44.3). Our results were similar to some previous studies, but different from other studies (Table 5) . Two studies showed mGPS as an independent prognostic factor for OS in SCLC patients. 6, 16 Although their patient backgrounds were different from ours, their result was consistent with ours. Compared with our study, including 33% (n=32) of mGPS 2, the proportions of mGPS 2 were much lower in those two previous studies: a Chinese and a Japanese study included only 3.1% (n=11) 6 and 22.9% (n=73), 16 respectively. Unlike our study that enrolled patients treated with chemotherapy alone, the Chinese study included 46.2% of patients treated with thoracic radiotherapy 6 and the Japanese study included 13.5% patients treated with supportive care alone. 16 Use of PNI as a prognostic factor for OS in SCLC is controversial. There have been two studies evaluating PNI as a prognostic factor for SCLC. One Chinese study demonstrated that PNI was a significant prognostic factor, independent of stage, performance status and LDH. 8 This study and ours detected PNI and PS as common independent prognostic factors. Another Chinese study included 919 patients, but failed to find PNI and PS as independent prognostic factors by multivariate analysis. In that study, patients with PNI ≥45 survived significantly longer than those with PNI <45. As a predictive marker for the efficacy of platinum-based first-line chemotherapy for SCLC, neither mGPS nor PNI was promising. In addition to a statistically insignificant difference in PFS between mGPS 0-1 vs 2 and high vs low PNI groups, neither mGPS nor PNI was found to be a significant predictive factor by multivariate analysis. To our knowledge, there are no studies investigating the association of mGPS and PNI with the efficacy of chemotherapy.
Our study has several limitations. First, it was a singlecentered, small-scale and retrospective study. Moreover, 13% of patients were lost to follow-up. The small number of patients and the high proportion lost to follow-up may account for the failure to identify the two biomarkers as significant predictive markers for the efficacy of chemotherapy. By contrast, both mGPS and PNI may be true prognostic markers for OS, because, despite the small size of the study, these indices were statistically significant and clinically relevant. Multicenter, prospective, large-scale studies should be conducted to validate this result. Second, patient selection was based on the availability of pretreatment blood tests. Our study excluded 6.7% of patients (7/104) due to lack of pretreatment laboratory data, a number that was much lower than reported in previous studies. Two Chinese studies excluded 22% (101/460) 6 and 40% (492/1216) 8 of SCLC patients during selection. Hong et al excluded 12% (146/1216) of patients owing to incomplete laboratory data. 8 Serum albumin measurement is not routine in clinical practice.
Conclusion
This was a small retrospective study, but we found that pretreatment mGPS and PNI were independent prognostic factors for OS in patients with advanced SCLC treated with chemotherapy. The pretreatment assessment of mGPS and PNI may be useful for identification of patients with poor prognosis. We recommend pretreatment testing for CRP, serum albumin and absolute lymphocyte count.
